From Surf Wiki (app.surf) — the open knowledge base

6,7-dihydropteridine reductase

Class of enzymes

Field	Value
Name	6,7-dihydropteridine reductase
EC_number	1.5.1.34
CAS_number	9074-11-7
GO_code	0004155
image	1hdr.jpg
width	270
caption	Dihydropteridine reductase dimer, Human

In enzymology, 6,7-dihydropteridine reductase (, also Dihydrobiopterin reductase) is an enzyme that catalyzes the chemical reaction

: 5,6,7,8-tetrahydropteridine + NAD(P)+ \rightleftharpoons 6,7-dihydropteridine + NAD(P)H + H+

The four substrates for this enzyme are a 6,7-dihydropteridine (dihydrobiopterin), NADH, NADPH, and H+ and its three products are 5,6,7,8-tetrahydropteridine (tetrahydrobiopterin), NAD+, and NADP+ This enzyme participates in folate biosynthesis. In the human genome, the enzyme is encoded by the QDPR gene.

Nomenclature

This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 5,6,7,8-tetrahydropteridine:NAD(P)+ oxidoreductase. Other names in common use include 6,7-dihydropteridine:NAD(P)H oxidoreductase, DHPR, NAD(P)H:6,7-dihydropteridine oxidoreductase, NADH-dihydropteridine reductase, NADPH-dihydropteridine reductase, NADPH-specific dihydropteridine reductase, dihydropteridine (reduced nicotinamide adenine dinucleotide), reductase, dihydropteridine reductase, dihydropteridine reductase (NADH), and 5,6,7,8-tetrahydropteridine:NAD(P)H+ oxidoreductase.

Clinical significance

Dihydropteridine reductase deficiency is a defect in the regeneration of tetrahydrobiopterin. Many patients have significant developmental delays despite therapy, develop brain abnormalities, and are prone to sudden death. The reason is not completely clear, but might be related to the accumulation of dihydrobiopterin and abnormal metabolism of folic acid. Response to treatment is variable and the long-term and functional outcome is unknown. To provide a basis for improving the understanding of the epidemiology, genotype/phenotype correlation and outcome of these diseases their impact on the quality of life of patients, and for evaluating diagnostic and therapeutic strategies a patient registry was established by the noncommercial International Working Group on Neurotransmitter Related Disorders (iNTD). Dihydropteridine reductase deficiency is treated with tyrosine supplements, a controlled diet which is lacking in phenylalanine, well as supplementation of L-DOPA.

References

(June 2009). "Disorders of biopterin metabolism". Journal of Inherited Metabolic Disease.
"Patient registry".
(2006). "Histology: a text and atlas: with correlated cell and molecular biology". Lippincott Williams & Wilkins.

Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

ec-1.5.1 nadph-dependent-enzymes nadh-dependent-enzymes enzymes-of-known-structure

Want to explore this topic further?

Ask Mako anything about 6,7-dihydropteridine reductase — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report